anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The hypothesis of the study is that the SmartDrive will enable the user to be more active, both in commuting longer distances with less strokes needed, and managing single difficulties stopping them from activity. The two assessments selected, distance travelled and the daily diary, should directly reflect the impact of the SmartDrive. In addition, the the International Spinal Cord Society (ISCoS) pain data set, Wheelchair User's Shoulder Pain Index (WUSPI) and Wheelchair Outcome Measure (WhOM) will be used. In WhOM, the participants will state some activities they perform in their wheelchair that are important to them, and how satisfied they are with their current level of performance of that activity. After the intervention period the satisfaction is reassessed. This will enable to capture the effect SmartDrive usage has on the participant's daily life (beyond distance commuted and pain level).

After enrollment, the participants will be followed for two weeks using their wheelchair without SmartDrive. After attaching the SmartDrive, they will have three weeks to get into a use of the device on a regular basis in their everyday life, and then follows two consecutive weeks of study intervention and data collection. To capture the long-term effect and allow for season variability, follow-up data will be collected at three and six months after start of study intervention.
The invention relates to the technical field of biological medicines, in particular to a targeted nano molecular probe and application thereof in preparing a tumor treatment medicine. The invention synthesizes the cell membrane nano vesicle which is over-expressed with a receptor corresponding to an immune check point and is provided with a Mcherry mark for the first time, and simultaneously prepares the targeting nano molecular probe by combining the melanin-loaded therapeutic drug. The overexpression immune checkpoint receptor marked by the Mcherry can better deliver chemotherapeutic drugs to tumor tissues by identifying LGALS9 on the surface of the tumor, realize the aggregation and effective killing of tumor cells and improve the immunotherapy defect of pancreatic cancer. Has the advantages of reducing administration times, improving curative effect, improving tolerance and the like, increases the retention time of the medicament in vivo, improves half-life period, prolongs absorption time and improves tumor targeting property. And the double effects of pancreatic cancer diagnosis and combined treatment are realized by utilizing magnetic resonance imaging. Has great advantages in tumor drug targeted delivery, real-time curative effect and dynamic monitoring.
<P>PROBLEM TO BE SOLVED: To provide a new tissue-engineered bone composition regarding the repair, recovery and tissue-engineering of the tissue-engineered bone composition, a bone tissue, a bone periodontal tissue.  <P>SOLUTION: The tissue-engineered bone composition contains amphiphilic peptide having self-organizing ability. In the presence of suitable electrolyte, the amphiphilic peptide forms nano fibers in the state of self-organizing and becomes peptide hydrogel. The peptide hydrogel functions as an osteogenic scaffold in a living body. The tissue-engineered bone composition is excellent in biocompatibility, and is excellent in flowability and formability, so that the defective or damaged section of the bone tissue or the bone periodontal tissue in the living body, for example, can be repaired, recovered and regenerated.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Rosacea is a long-term inflammatory skin disease associated with the dysfunction of vascular and immunological systems. Treatment options for rosacea are difficult to implement. Oroxylin A(OA), a traditional Chinese medicine, has anti-inflammation effects in a variety of inflammatory diseases. However, it is not known that whether OA exerts protective effects against LL-37-induced rosacea. In this study, bioinformatics analyses showed that the mechanisms of rosacea and the pharmacological targets of OA were highly overlapped. Subsequently, it was shown that the administration of OA resulted in a notable amelioration of rosacea-like skin lesions, as evidenced by a reduction in immune cell infiltration, modulation of cytokine production, and inhibition of angiogenesis. Plus, it was shown that OA effectively suppressed the generation of ROS generated by LL-37, as well as the subsequent activation of NF-κB signaling pathway. To explore further, we found that OA inhibited LL-37-induced ROS production via SIRT3-SOD2 signaling pathway in keratinocytes. Based on the aforementioned evidence, it can be inferred that OA exhibits a mitigating effect on the inflammatory response in rosacea by modulating the SIRT3-SOD2-NF-κB signaling pathway.
BACKGROUND: Globally, cardiovascular disease (CVD) constitutes the primary cause of death, with insulin resistance (IR), measured by the triglyceride-glucose (TyG) index, and visceral obesity, reflected by the Chinese Visceral Adiposity Index (CVAI), as key contributors. However, the relationship between the TyG index and CVAI regarding CVD risk remains insufficiently understood. This research investigates the interactive impact of the TyG index and CVAI on the risk of cardiovascular disease.
METHODS: We analyzed data from 8,358 participants from the China Health and Retirement Longitudinal Study (CHARLS) over a 9-year follow-up period. Participants were classified into four groups based on median TyG index (8.59) and CVAI values (101.26), and baseline characteristics were summarized. Missing data were addressed using multiple imputation by chained equations (MICE). Cox proportional hazards models assessed associations between TyG index, CVAI, CVD, coronary heart disease (CHD), and stroke risks, with Kaplan-Meier analysis used for cumulative hazard. Interaction effects were evaluated using both multiplicative and additive measures. Subgroup analyses by age, gender, and clinical conditions were conducted to explore interaction effects across different populations. Sensitivity analyses re-tested models, excluding the covariates BMI and diabetes, using tertiles for classification, and re-evaluating imputed data.
RESULTS: Over the 9-year follow-up, 1,240 participants (14.8%) developed CVD, including 896 cases of CHD and 475 strokes. Kaplan-Meier curves indicated that participants with low TyG index but high CVAI had the highest cumulative hazard of CVD. Cox regression showed that this group had the highest CVD risk (HR = 1.87, 95% CI: 1.57-2.24), followed by those with both high TyG index and high CVAI (HR = 1.75, 95% CI: 1.49-2.06). Interaction analysis revealed a negative interaction effect between high TyG and high CVAI on CVD and CHD risks, with no significant effect on stroke. Subgroup and sensitivity analyses further confirmed these findings, showing consistent results across demographic groups and under various analytical conditions.
CONCLUSION: This study suggests that the interaction between IR (TyG index) and visceral fat accumulation (CVAI) plays a complex role in CVD risk, with a potential antagonistic effect observed between high TyG and high CVAI on CVD events. These findings highlight the importance of considering both IR and visceral adiposity in CVD risk assessments to improve the identification of high-risk individuals.
<P>PROBLEM TO BE SOLVED: To provide compositions and methods for the treatment and diagnosis of cancer (particularly, lung cancer).  <P>SOLUTION: The illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen-presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer. Such polypeptide and/or polynucleotide may be used in pharmacological compositions (e.g. vaccines) for the diagnosis and treatment of lung cancer, and in other compositions.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Infective endocarditis is a rare but life-threatening condition, occasionally linked to diverse immunologic manifestations, including mixed cryoglobulinemia. This can lead to cryoglobulinemic vasculitis, which has the potential for widespread organ damage. Although some cases have highlighted the relationship between infective endocarditis and cryoglobulinemic vasculitis, no comprehensive epidemiological evaluation or optimal treatment strategies have been advanced for such a combination. We present a case of methicillin-sensitive Staphylococcus aureus infective endocarditis associated with cryoglobulinemic vasculitis and conduct a literature review to compare management and outcomes in similar cases. Our patient presented with classical Meltzer's triad and mild renal involvement. Cryoimmunofixation confirmed type III cryoglobulinemia, and serum cytokines showed elevated IL-6 levels. The differential diagnosis included infective endocarditis and chronic active hepatitis C virus infection. Rapid symptom resolution after antibiotic treatment identified infective endocarditis as the likely cause of cryoglobulinemic vasculitis. Our case and review of the literature highlight that early identification of the cause of cryoglobulinemic vasculitis is crucial for selecting appropriate treatment and preventing recurrence or morbidity.
<P>PROBLEM TO BE SOLVED: To provide a pigment prepared by coating the surface of a layered alkali metal polysilicate with a metal oxide; to provide a pearl pigment at a low price whose size and shape are easily controlled; and to provide a composition comprising the pearl pigment prepared by coating the surface of a layered alkali metal polysilicate with a metal oxide.  <P>SOLUTION: The pigment comprises a layered alkali metal polysilicate as a substrate, wherein the surface thereof is coated with a metal oxide. The layered alkali metal polysilicate can include sodium salts such as makatite, ilerite, magadiite, and kenyaite. The metal oxide can include titanium oxide, iron oxide and the like. The pearl pigment preferably has an average particle size of 2-200 μm and an average thickness of 0.01-5 μm.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
This is an open label, phase II, investigator-initiated clinical trial of 50 subjects. Subjects with CLL/SLL who have treatment indications per the 2018 International Workshop for CLL (iwCLL) will be eligible to enroll. The investigators hypothesize that anti-CD20 therapy may not be required for all patients and a response-adapted strategy will prevent over treatment of a significant number of patients and reduce toxicity of treatment while still achieving a high rate of MRD negativity. The investigators also hypothesize that late addition of anti-CD20 therapy can eliminate low burden residual disease in subjects and maximize undetectable MRD negativity in subjects who remain MRD positive.

All subjects will initiate induction therapy with 3 cycles of zanubrutinib monotherapy in order to debulk subjects and mitigate tumor lysis risk. This lead-in period will then be followed by 12 cycles of zanubrutinib and venetoclax combination. Standard ramp-up protocols for venetoclax based on TLS risk assessed prior to C4D1 will be utilized. All subjects will complete 12 cycles of zanubrutinib and venetoclax combination therapy or 15 cycles of total treatment. Peripheral blood and bone marrow MRD assessments will occur at C16D1. Subjects will continue on combination treatment for an additional 1 month while results of MRD testing are obtained. In total, all subjects will be on treatment for at least 16 full cycles. Subjects that meet definition of MRD negativity will stop therapy at C17D1 and enter an observation phase with study visits every 3 months. Subjects that meet definition of MRD positivity will continue combination therapy with zanubrutinib and venetoclax, but will also receive 6 cycles of obinutuzumab starting at C17D1. In this subgroup, peripheral blood and bone marrow MRD assessments will occur after an additional 6 cycles of the triplet combination therapy (C23D1) at which point all subjects will stop study treatment regardless of MRD status.
When a patient will present a suspicion of VAP (Clinical Pulmonary Infection Score modified ≥ 5), Simvastatin or placebo will be administered with antibiotics. Quantitative cultures will be performed for microbiological confirmation of VAP. Simvastatin or placebo will be administered through an enteral feeding tube or administered orally when patients are able to safely take oral medications. The type and placement of the enteral feeding tube (nasogastric, nasoenteric, PEG, orogastric, oroenteric, etc.) and the ability to safely take oral medications will be determined by the patient's primary team. Study drug will be blinded with an identical appearing placebo.

Sequential Organ Failure Assessment score (SOFA), and various blood factors will be measured during treatment.
PURPOSE: To clarify the characteristics of intraocular lens (IOL) dislocation requiring IOL suture or intraocular scleral fixation.
METHODS: This retrospective consecutive case series included 21 eyes (21 patients) who required sutured or sutureless intrascleral IOL fixation following IOL extraction owing to IOL dislocation at the outpatient clinic in the Department of Ophthalmology, Saitama Red Cross Hospital, Japan, between January and December 2019. Medical records were retrospectively reviewed for background diseases, location of the dislocated IOL (intracapsular/extracapsular), insertion of a capsular tension ring (CTR), and the period from IOL insertion to dislocation.
RESULTS: We included 21 eyes of 21 patients who required IOL suture or intrascleral fixation for IOL dislocation at our clinic from January to December 2019 were included. The most common background disease was pseudoexfoliation syndrome (four cases), followed by atopic dermatitis, dysplasia/dehiscence of the zonule, post-retinal detachment surgery, high myopia, and uveitis (three cases each). At the time of dislocation, the IOLs were either intracapsular (16 cases, including 3 cases with CTR insertion) or extracapsular (5 cases). The time from IOL insertion to IOL dislocation was 13.7 ± 8.1 years (maximum: 31.3 years, minimum: 1.7 years).
CONCLUSIONS: In this study, all 21 cases represented late IOL dislocations occurring after 3 months postoperatively. Among these late IOL dislocation cases, IOL dislocation occurred in a short-medium period of time, especially in those with CTR insertion and weakness/dehiscence of the zonule, with an average of 3 to 5 years postoperatively. We propose referring to these cases as intermediate-term IOL dislocation.
PURPOSE: Eupatorium chinensis var. simplicifolium extracts is provided to exhibit excellent inhibition activity of muscular atrophy, thereby being usefully used for the prevention, treatment and improvement of muscular atrophy. CONSTITUTION: A pharmaceutical composition for the prevention and treatment of muscular atrophy includes eupatorium chinensis var. simplicifolium extracts as an active ingredient. A food composition for the improvement of muscular atrophy includes eupatorium chinensis var. simplicifolium extracts as an active ingredient. The muscular atrophy is generated by the loss of muscle tissue due to disused muscle, muscular diseases or damage to nerves innervating muscle. [Reference numerals] (AA) Cell survival rate (%); (BB) Eupatorium chinensis var. simplicifolium extracts
PROBLEM TO BE SOLVED: To obtain a composition having activity for enhancing insulin action and differentiation-inducing activity by including a compound having lanostane skeleton or 3,4-secolanostane skeleton as an active ingredient. SOLUTION: This composition has at least one kind of compound among compounds of formula I (R1 is H or CH3 ; R2 A is β-OH, β-OCOCH3 , α-OH, etc.; R3 is H or OH; R4 is C(=CH2 )-C(CH3 )2 -Ra , etc.; Ra is H or OH; R6 is CH3 or CH2 OH), etc., and compounds of formula II (R2 B is H or CH3 ; R5 is H or OH). The compound of formula I includes e.g. polyporenic acid C or 3-O-acetyl-16 α-hydroxytrametenolic acid and the compound of formula II includes e.g. polycoic acid A. These compounds are obtained by extracting Hoelen or dried skin of pachyma hoelen which is a crude medicine. These compounds or the extracts are used as compositions such as pharmaceutical preparations, preparations for external uses, cosmetic compositions, functional foods or health foods.
Cosmetic and dermopharmaceutical compositions containing an extract of Centaurium, esp. Centaurium erythraea (I) are new.  The whole, aerial or flowering parts of the fresh or dried plant are extracted pref. by known methods (e.g. by refluxing, or ultrasound or microwave treatment) using a 1-4C alcohol, a ketone, ether and/or an aliphatic or cyclic alkane. Preferred solvents are fatty alcohols or their esters, or polyethylene or polypropylene glycol ethers. The extract may pref. be used in liq. or dried form and comprises 0.5 - 10 wt. % of the compsn. which is in the form of e.g. oil-in-water and water-in-oil emulsions, lotions, gels or ointments The extracts may be incorporated into cosmetic vehicles such as liposomes, macro-, micro and nanoparticles.
PURPOSE:To prepare a perfume which has a particular aroma and is useful for aromatizing, such as a perfume for perfumed water and shampoo and a flavor for dentifrice and cookie, by using a methylthioalkylbenzene compd. as an active ingredient. CONSTITUTION:A monosubstituted sodium thiophenolate obtd. by neutralizing a compd. of formula I (wherein R is a 1-8C alkyl) with NaOH is reacted with CH3I. The reaction product is extracted, washed, and distilled to obtain a methylthioalkylbenzene compd. of formula II. It is used as an active ingredient. If necessary, it is mixed additives such as blenders, matching agents, modifiers, fixing agents, solvents, higher alcohols, surfactants and pigments and auxiliary components such as reinforcing agents and enhancers.
The present invention discloses medicine for treating rhinitis and a preparation method thereof, particularly medicine for treating rhinitis and a preparation method thereof. The present invention belongs to medicine mainly containing traditional Chinese medicine and a preparation method thereof. The medicine for treating rhinitis is composed of the raw materials of honeycombs, scorpions, centipedes, snake sloughs, sesame oil, vinegar, wine and sulfamethoxazole. The medicine of the present invention integrates various kinds of traditional Chinese medicine having the efficacy of activating meridians to stop pain, expelling wind for detoxication, expelling wind, eliminating dampness, resolving mass and swelling and promoting blood circulation to stop pain for reasonable compatibility. The sulfamethoxazole as western medicine has good functions of sterilization and anti-inflammation. The traditional Chinese medicine and the western medicine are mutually promoted, replenished and matched. By clinical verification, the present invention has the advantages of good curative effect and no side effect.
Patients receive panitumumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for a maximum of 24 cycles in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Sensory prediction allows the brain to anticipate and parse incoming self-generated sensory information from externally generated signals. Sensory prediction breakdowns may contribute to perceptual and agency abnormalities in psychosis (hallucinations, delusions). The pons, a central node in a cortico-ponto-cerebellar-thalamo-cortical circuit, is thought to support sensory prediction. Examination of pons connectivity in schizophrenia and its role in sensory prediction abnormalities is lacking.
METHODS: We examined these relationships using resting-state functional magnetic resonance imaging and the electroencephalography-based auditory N1 event-related potential in 143 participants with psychotic spectrum disorders (PSPs) (with schizophrenia, schizoaffective disorder, or bipolar disorder); 63 first-degree relatives of individuals with psychosis; 45 people at clinical high risk for psychosis; and 124 unaffected comparison participants. This unique sample allowed examination across the psychosis spectrum and illness trajectory. Seeding from the pons, we extracted average connectivity values from thalamic and cerebellar clusters showing differences between PSPs and unaffected comparison participants. We predicted N1 amplitude attenuation during a vocalization task from pons connectivity and group membership. We correlated participant-level connectivity in PSPs and people at clinical high risk for psychosis with hallucination and delusion severity.
RESULTS: Compared to unaffected comparison participants, PSPs showed pons hypoconnectivity to 2 cerebellar clusters, and first-degree relatives of individuals with psychosis showed hypoconnectivity to 1 of these clusters. Pons-to-cerebellum connectivity was positively correlated with N1 attenuation; only PSPs with heightened pons-to-postcentral gyrus connectivity showed this pattern, suggesting a possible compensatory mechanism. Pons-to-cerebellum hypoconnectivity was correlated with greater hallucination severity specifically among PSPs with schizophrenia.
CONCLUSIONS: Deficient pons-to-cerebellum connectivity linked sensory prediction network breakdowns with perceptual abnormalities in schizophrenia. Findings highlight shared features and clinical heterogeneity across the psychosis spectrum.
Vitamins and sterols are extracted from animal or vegetable fats or oils by saponifying the fats or oils with an aqueous solution of sodium hydroxide of such a concentration that a solid soap containing less than 20 per cent water by weight is obtained, after cooling, subdividing said soap to uniform solid soap particles and extracting the soap particles with a water-miscible aliphatic ketone or water-miscible aliphatic monohydric alcohol in such quantities that the water content of the solution is less than 5 per cent by weight when equilibrium is reached.  The water miscible solvent may be acetone, methyl ethyl ketone, methanol, ethanol or isopropanol.  The process may be modified in that the saponification is carried out with aqueous sodium hydroxide of such a concentration that a soap containing more than 20 per cent of water by weight is obtained, and the soap so obtained is dried and subdivided to obtain uniform soap particles containing less than 20 per cent water.  The aqueous sodium hydroxide solution may contain between 40 and 60 per cent by weight of sodium hydroxide. A saponification catalyst, e.g. 1 per cent by weight of a monohydric alcohol, may be used in the saponification step.  Some glycerin is extracted by the solvent and may be recovered by extracting the extracted matter after the removal of the solvent with small quantities of water.  One detailed example is given.